Clinical effectiveness and speed of response of electroconvulsive therapy in treatment‐resistant schizophrenia

Aim Although electroconvulsive therapy (ECT) has been shown to be efficacious for patients with treatment‐resistant schizophrenia, there has been limited evidence on the rate of response, cognition, and quality‐of‐life outcomes. The primary aims of the present study were thus to examine the effectiv...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Psychiatry and clinical neurosciences Ročník 73; číslo 7; s. 416 - 422
Hlavní autori:	Chan, Christopher Yi Wen, Abdin, Edimansyah, Seow, Esmond, Subramaniam, Mythily, Liu, Jianlin, Peh, Chao Xu, Tor, Phern Chern
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Melbourne John Wiley & Sons Australia, Ltd 01.07.2019 Wiley Subscription Services, Inc
Predmet:	Adult cognition Cognitive ability Electroconvulsive Therapy Female Humans Male Mental disorders Middle Aged neurostimulation Patients Psychiatric Status Rating Scales Psychosis Quality of Life Retrospective Studies Schizophrenia Schizophrenia - therapy Time Factors Treatment Outcome Treatment resistance treatment‐resistant schizophrenia Young Adult electroconvulsive therapy treatment-resistant schizophrenia cognition quality of life neurostimulation
ISSN:	1323-1316, 1440-1819, 1440-1819
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Aim Although electroconvulsive therapy (ECT) has been shown to be efficacious for patients with treatment‐resistant schizophrenia, there has been limited evidence on the rate of response, cognition, and quality‐of‐life outcomes. The primary aims of the present study were thus to examine the effectiveness and speed of response to ECT in a naturalistic retrospective cohort in patients with treatment‐resistant schizophrenia. Methods We performed a retrospective database analysis. The primary effectiveness outcome was defined as an improvement of ≥40% from pretreatment scores based on the Brief Psychiatric Rating Scale (BPRS) Psychotic Symptom subscale. Data were included for analysis for all patients with a primary DSM‐5 diagnosis of schizophrenia that was treatment‐resistant and who had had an acute course of ECT initiated for the treatment of schizophrenia between 1 July 2016 and 1 December 2016. Results A total of 50 inpatients were included for analysis. The present study revealed that 50% of patients showed at least a 40% reduction in BPRS Psychotic Symptom subscale scores after completion of ECT and that 16.7% of patients responded after the first three sessions, 39.3% after six sessions, 46.4% after nine sessions, and 50% after 12 sessions. The greatest improvement in BPRS scores was between the third and sixth ECT sessions. BPRS scores, Clinical Global Impression, Montreal Cognitive Assessment, and Global Assessment of Functioning showed significant improvement. There was no significant difference in quality‐of‐life outcomes. Conclusion Utilizing modern techniques in treatment‐resistant schizophrenia, this study demonstrates the real‐world effectiveness and rate of response of patients receiving ECT.
AbstractList	Although electroconvulsive therapy (ECT) has been shown to be efficacious for patients with treatment-resistant schizophrenia, there has been limited evidence on the rate of response, cognition, and quality-of-life outcomes. The primary aims of the present study were thus to examine the effectiveness and speed of response to ECT in a naturalistic retrospective cohort in patients with treatment-resistant schizophrenia.AIMAlthough electroconvulsive therapy (ECT) has been shown to be efficacious for patients with treatment-resistant schizophrenia, there has been limited evidence on the rate of response, cognition, and quality-of-life outcomes. The primary aims of the present study were thus to examine the effectiveness and speed of response to ECT in a naturalistic retrospective cohort in patients with treatment-resistant schizophrenia.We performed a retrospective database analysis. The primary effectiveness outcome was defined as an improvement of ≥40% from pretreatment scores based on the Brief Psychiatric Rating Scale (BPRS) Psychotic Symptom subscale. Data were included for analysis for all patients with a primary DSM-5 diagnosis of schizophrenia that was treatment-resistant and who had had an acute course of ECT initiated for the treatment of schizophrenia between 1 July 2016 and 1 December 2016.METHODSWe performed a retrospective database analysis. The primary effectiveness outcome was defined as an improvement of ≥40% from pretreatment scores based on the Brief Psychiatric Rating Scale (BPRS) Psychotic Symptom subscale. Data were included for analysis for all patients with a primary DSM-5 diagnosis of schizophrenia that was treatment-resistant and who had had an acute course of ECT initiated for the treatment of schizophrenia between 1 July 2016 and 1 December 2016.A total of 50 inpatients were included for analysis. The present study revealed that 50% of patients showed at least a 40% reduction in BPRS Psychotic Symptom subscale scores after completion of ECT and that 16.7% of patients responded after the first three sessions, 39.3% after six sessions, 46.4% after nine sessions, and 50% after 12 sessions. The greatest improvement in BPRS scores was between the third and sixth ECT sessions. BPRS scores, Clinical Global Impression, Montreal Cognitive Assessment, and Global Assessment of Functioning showed significant improvement. There was no significant difference in quality-of-life outcomes.RESULTSA total of 50 inpatients were included for analysis. The present study revealed that 50% of patients showed at least a 40% reduction in BPRS Psychotic Symptom subscale scores after completion of ECT and that 16.7% of patients responded after the first three sessions, 39.3% after six sessions, 46.4% after nine sessions, and 50% after 12 sessions. The greatest improvement in BPRS scores was between the third and sixth ECT sessions. BPRS scores, Clinical Global Impression, Montreal Cognitive Assessment, and Global Assessment of Functioning showed significant improvement. There was no significant difference in quality-of-life outcomes.Utilizing modern techniques in treatment-resistant schizophrenia, this study demonstrates the real-world effectiveness and rate of response of patients receiving ECT.CONCLUSIONUtilizing modern techniques in treatment-resistant schizophrenia, this study demonstrates the real-world effectiveness and rate of response of patients receiving ECT. AimAlthough electroconvulsive therapy (ECT) has been shown to be efficacious for patients with treatment‐resistant schizophrenia, there has been limited evidence on the rate of response, cognition, and quality‐of‐life outcomes. The primary aims of the present study were thus to examine the effectiveness and speed of response to ECT in a naturalistic retrospective cohort in patients with treatment‐resistant schizophrenia.MethodsWe performed a retrospective database analysis. The primary effectiveness outcome was defined as an improvement of ≥40% from pretreatment scores based on the Brief Psychiatric Rating Scale (BPRS) Psychotic Symptom subscale. Data were included for analysis for all patients with a primary DSM‐5 diagnosis of schizophrenia that was treatment‐resistant and who had had an acute course of ECT initiated for the treatment of schizophrenia between 1 July 2016 and 1 December 2016.ResultsA total of 50 inpatients were included for analysis. The present study revealed that 50% of patients showed at least a 40% reduction in BPRS Psychotic Symptom subscale scores after completion of ECT and that 16.7% of patients responded after the first three sessions, 39.3% after six sessions, 46.4% after nine sessions, and 50% after 12 sessions. The greatest improvement in BPRS scores was between the third and sixth ECT sessions. BPRS scores, Clinical Global Impression, Montreal Cognitive Assessment, and Global Assessment of Functioning showed significant improvement. There was no significant difference in quality‐of‐life outcomes.ConclusionUtilizing modern techniques in treatment‐resistant schizophrenia, this study demonstrates the real‐world effectiveness and rate of response of patients receiving ECT. Although electroconvulsive therapy (ECT) has been shown to be efficacious for patients with treatment-resistant schizophrenia, there has been limited evidence on the rate of response, cognition, and quality-of-life outcomes. The primary aims of the present study were thus to examine the effectiveness and speed of response to ECT in a naturalistic retrospective cohort in patients with treatment-resistant schizophrenia. We performed a retrospective database analysis. The primary effectiveness outcome was defined as an improvement of ≥40% from pretreatment scores based on the Brief Psychiatric Rating Scale (BPRS) Psychotic Symptom subscale. Data were included for analysis for all patients with a primary DSM-5 diagnosis of schizophrenia that was treatment-resistant and who had had an acute course of ECT initiated for the treatment of schizophrenia between 1 July 2016 and 1 December 2016. A total of 50 inpatients were included for analysis. The present study revealed that 50% of patients showed at least a 40% reduction in BPRS Psychotic Symptom subscale scores after completion of ECT and that 16.7% of patients responded after the first three sessions, 39.3% after six sessions, 46.4% after nine sessions, and 50% after 12 sessions. The greatest improvement in BPRS scores was between the third and sixth ECT sessions. BPRS scores, Clinical Global Impression, Montreal Cognitive Assessment, and Global Assessment of Functioning showed significant improvement. There was no significant difference in quality-of-life outcomes. Utilizing modern techniques in treatment-resistant schizophrenia, this study demonstrates the real-world effectiveness and rate of response of patients receiving ECT. Aim Although electroconvulsive therapy (ECT) has been shown to be efficacious for patients with treatment‐resistant schizophrenia, there has been limited evidence on the rate of response, cognition, and quality‐of‐life outcomes. The primary aims of the present study were thus to examine the effectiveness and speed of response to ECT in a naturalistic retrospective cohort in patients with treatment‐resistant schizophrenia. Methods We performed a retrospective database analysis. The primary effectiveness outcome was defined as an improvement of ≥40% from pretreatment scores based on the Brief Psychiatric Rating Scale (BPRS) Psychotic Symptom subscale. Data were included for analysis for all patients with a primary DSM‐5 diagnosis of schizophrenia that was treatment‐resistant and who had had an acute course of ECT initiated for the treatment of schizophrenia between 1 July 2016 and 1 December 2016. Results A total of 50 inpatients were included for analysis. The present study revealed that 50% of patients showed at least a 40% reduction in BPRS Psychotic Symptom subscale scores after completion of ECT and that 16.7% of patients responded after the first three sessions, 39.3% after six sessions, 46.4% after nine sessions, and 50% after 12 sessions. The greatest improvement in BPRS scores was between the third and sixth ECT sessions. BPRS scores, Clinical Global Impression, Montreal Cognitive Assessment, and Global Assessment of Functioning showed significant improvement. There was no significant difference in quality‐of‐life outcomes. Conclusion Utilizing modern techniques in treatment‐resistant schizophrenia, this study demonstrates the real‐world effectiveness and rate of response of patients receiving ECT.
Author	Tor, Phern Chern Liu, Jianlin Peh, Chao Xu Subramaniam, Mythily Seow, Esmond Chan, Christopher Yi Wen Abdin, Edimansyah
Author_xml	– sequence: 1 givenname: Christopher Yi Wen orcidid: 0000-0001-5793-8495 surname: Chan fullname: Chan, Christopher Yi Wen email: christopher_yw_chan@imh.com.sg organization: Institute of Mental Health – sequence: 2 givenname: Edimansyah surname: Abdin fullname: Abdin, Edimansyah organization: Institute of Mental Health – sequence: 3 givenname: Esmond surname: Seow fullname: Seow, Esmond organization: Institute of Mental Health – sequence: 4 givenname: Mythily surname: Subramaniam fullname: Subramaniam, Mythily organization: Institute of Mental Health – sequence: 5 givenname: Jianlin surname: Liu fullname: Liu, Jianlin organization: Institute of Mental Health – sequence: 6 givenname: Chao Xu surname: Peh fullname: Peh, Chao Xu organization: Institute of Mental Health – sequence: 7 givenname: Phern Chern orcidid: 0000-0001-7972-3030 surname: Tor fullname: Tor, Phern Chern organization: Institute of Mental Health
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/31026106$$D View this record in MEDLINE/PubMed
BookMark	eNp90c1O3DAQB3Croiof7aEvUFnqBQ4Bj5144yNaFaiEaA_tOXKcidbIa6e2A9qeeASesU9Sw1IOSNQXj6zfjEb-75MdHzwS8hHYMZRzMhl_DLxtmjdkD-qaVdCC2im14KICAXKX7Kd0zRgTQsI7siuAcQlM7pFp6ay3RjuK44gm2xv0mBLVfqBpQhxoGGnENAWf8KFGV1QMJvib2aXCaV5h1NOGWk9zRJ3X6POfu_vSZFPWPtNkVvZ3mFYRvdXvydtRu4Qfnu4D8vPsy4_lRXX57fzr8vSyMvWibSpU7WIYeF8r4CCZkSikGEEiqAEV6015b3iLSmswXAHUGsaG1Yu-RtZrJg7I4XbuFMOvGVPu1jYZdE57DHPqeBnLleDAC_38gl6HOfqyXVFN3XKp2raoT09q7tc4dFO0ax033b-_LOBoC0wMKUUcnwmw7iGnruTUPeZU7MkLa2zW2Qafo7bufx231uHm9dHd9-XVtuMvclylfg
CitedBy_id	crossref_primary_10_1111_pcn_13489 crossref_primary_10_1016_j_ypsc_2024_05_013 crossref_primary_10_1016_j_psychres_2025_116374 crossref_primary_10_1016_j_psychres_2023_115580 crossref_primary_10_1017_neu_2021_40 crossref_primary_10_3389_fpsyt_2023_1127262 crossref_primary_10_1016_j_psycr_2025_100280 crossref_primary_10_1097_YCT_0000000000001183 crossref_primary_10_1038_s41380_022_01572_0 crossref_primary_10_1093_schbul_sbac027 crossref_primary_10_1097_YCT_0000000000000690 crossref_primary_10_1056_NEJMra2034954 crossref_primary_10_1111_acps_13134 crossref_primary_10_1097_YCT_0000000000001012 crossref_primary_10_1192_bjo_2023_37 crossref_primary_10_1016_j_euroneuro_2021_04_023 crossref_primary_10_1097_YCT_0000000000000747 crossref_primary_10_1016_j_schres_2025_08_018 crossref_primary_10_1111_jpm_12778 crossref_primary_10_1016_j_aan_2022_07_005 crossref_primary_10_1016_j_jpsychires_2025_09_004 crossref_primary_10_1016_j_jpsychires_2024_09_045 crossref_primary_10_1016_j_psycr_2022_100052 crossref_primary_10_1016_j_jpsychires_2024_07_012 crossref_primary_10_3389_fpsyt_2022_1005373 crossref_primary_10_1097_YCT_0000000000001050 crossref_primary_10_3390_jcm12175728 crossref_primary_10_1097_YCT_0000000000001101 crossref_primary_10_1186_s12888_021_03053_0 crossref_primary_10_1177_15500594211058260 crossref_primary_10_1097_YCT_0000000000001108 crossref_primary_10_1177_15500594211025889 crossref_primary_10_1002_wps_21159 crossref_primary_10_3390_brainsci12050545 crossref_primary_10_3390_biomedicines12112637
Cites_doi	10.1016/j.eurpsy.2011.10.002 10.1097/YCT.0000000000000422 10.4088/JCP.16m10686 10.1007/s00406-010-0173-3 10.1016/j.brs.2012.04.002 10.1097/00124509-200409000-00006 10.1192/bjp.bp.109.066183 10.1016/j.schres.2007.09.001 10.1016/j.apnu.2015.08.016 10.1093/schbul/sbl071 10.1016/0165-1781(84)90065-9 10.1176/appi.ajp.2016.16050503 10.1016/j.biopsych.2010.06.009 10.1177/0706743717718167 10.1007/s11136-011-9903-x 10.1016/S0920-9964(02)00330-4 10.1016/j.jad.2010.02.134 10.1097/YCT.0b013e3181cb5e0f 10.1037/1541-1559.3.2.77 10.2147/NDT.S90143 10.1176/appi.ajp.162.3.441 10.1016/j.schres.2011.09.021 10.1016/S0022-510X(09)71062-7 10.1097/01.pra.0000361277.65468.ef 10.31887/DCNS.2014.16.2/drevicki 10.1056/NEJMra0707755 10.2466/pr0.1962.10.3.799 10.1016/j.schres.2014.07.006 10.1016/j.schres.2016.05.002 10.1016/j.psychres.2016.09.046 10.1097/00124509-199909000-00004 10.1080/00048670802050512 10.1176/jnp.10.2.178 10.2147/NDT.S73992 10.1097/01.yct.0000235922.14623.39 10.1176/appi.ajp.2014.13060787
ContentType	Journal Article
Copyright	2019 The Authors. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology 2019 The Authors. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology. 2019 The Author. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology
Copyright_xml	– notice: 2019 The Authors. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology – notice: 2019 The Authors. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology. – notice: 2019 The Author. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7TK K9. 7X8
DOI	10.1111/pcn.12855
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Neurosciences Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Health & Medical Complete (Alumni) Neurosciences Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic ProQuest Health & Medical Complete (Alumni) MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1440-1819
EndPage	422
ExternalDocumentID	31026106 10_1111_pcn_12855 PCN12855
Genre	article Journal Article
GroupedDBID	--- .3N .55 .GA .Y3 05W 0R~ 10A 123 1OB 1OC 24P 29P 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABDBF ABEML ABIVO ABJNI ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACRPL ACSCC ACUHS ACXBN ACXQS ACYXJ ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AHEFC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 DUUFO E3Z EAD EAP EBC EBD EBS EJD EMB EMK EMOBN EPS ESX EX3 F00 F01 F04 F5P FEDTE FUBAC G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IHE IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TKC TR2 TUS UB1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH ZXP ZZTAW ~02 ~IA ~WT AAMMB AAYXX AEFGJ AEYWJ AGHNM AGQPQ AGXDD AGYGG AIDQK AIDYY CITATION O8X CGR CUY CVF ECM EIF NPM 7TK K9. 7X8
ID	FETCH-LOGICAL-c4785-e987dd2b4912160c6e363f16e19de90bc912528e9aa1c29114a1f5047b4e0ba03
IEDL.DBID	DRFUL
ISICitedReferencesCount	35
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000474931200008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1323-1316 1440-1819
IngestDate	Thu Sep 04 18:28:35 EDT 2025 Sat Nov 29 14:38:05 EST 2025 Thu Apr 03 07:01:36 EDT 2025 Sat Nov 29 05:59:58 EST 2025 Tue Nov 18 20:57:45 EST 2025 Wed Jan 22 16:40:05 EST 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Keywords	electroconvulsive therapy treatment-resistant schizophrenia cognition quality of life neurostimulation
Language	English
License	2019 The Authors. Psychiatry and Clinical Neurosciences © 2019 Japanese Society of Psychiatry and Neurology.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4785-e987dd2b4912160c6e363f16e19de90bc912528e9aa1c29114a1f5047b4e0ba03
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0001-7972-3030 0000-0001-5793-8495
OpenAccessLink	https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/pcn.12855
PMID	31026106
PQID	2254826988
PQPubID	1106347
PageCount	7
ParticipantIDs	proquest_miscellaneous_2216293212 proquest_journals_2254826988 pubmed_primary_31026106 crossref_primary_10_1111_pcn_12855 crossref_citationtrail_10_1111_pcn_12855 wiley_primary_10_1111_pcn_12855_PCN12855
PublicationCentury	2000
PublicationDate	July 2019
PublicationDateYYYYMMDD	2019-07-01
PublicationDate_xml	– month: 07 year: 2019 text: July 2019
PublicationDecade	2010
PublicationPlace	Melbourne
PublicationPlace_xml	– name: Melbourne – name: Australia – name: Tokyo
PublicationTitle	Psychiatry and clinical neurosciences
PublicationTitleAlternate	Psychiatry Clin Neurosci
PublicationYear	2019
Publisher	John Wiley & Sons Australia, Ltd Wiley Subscription Services, Inc
Publisher_xml	– name: John Wiley & Sons Australia, Ltd – name: Wiley Subscription Services, Inc
References	2017; 62 2004; 20 2017; 1 1993; 29 2013; 28 2012 2010; 126 2015; 11 2016; 30 2006; 3 2008; 98 2017; 174 1962; 10 2016; 246 2007; 33 2013; 6 2014; 158 2011; 133 1996; 12 2015; 172 2010; 26 2005; 162 2015; 27 2010; 68 2006; 22 1984; 11 1999; 15 2017; 78 2014; 16 2011; 20 2010; 196 2009; 360 2009; 285 2008; 42 2011; 261 1998; 10 2003; 63 2016; 174 2009; 15 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_8_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_16_1 e_1_2_7_40_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_41_1 e_1_2_7_14_1 e_1_2_7_42_1 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_11_1 e_1_2_7_10_1 Revicki DA (e_1_2_7_9_1) 2014; 16 e_1_2_7_26_1 e_1_2_7_27_1 e_1_2_7_28_1 e_1_2_7_29_1 Garg R (e_1_2_7_34_1) 2011; 133 Endicott J (e_1_2_7_25_1) 1993; 29 Wang W (e_1_2_7_30_1) 2015; 27 e_1_2_7_31_1 e_1_2_7_24_1 e_1_2_7_32_1 e_1_2_7_33_1 e_1_2_7_22_1 e_1_2_7_21_1 e_1_2_7_35_1 e_1_2_7_20_1 e_1_2_7_36_1 e_1_2_7_37_1 e_1_2_7_38_1 e_1_2_7_39_1 McCall WV (e_1_2_7_23_1) 1996; 12
References_xml	– volume: 16 start-page: 127 year: 2014 end-page: 135 article-title: A history of health‐related quality of life outcomes in psychiatry publication-title: Dialogues Clin. Neurosci. – volume: 22 start-page: 213 year: 2006 end-page: 217 article-title: Ictal electroencephalographic characteristics during electroconvulsive therapy publication-title: J. ECT – volume: 30 start-page: 210 year: 2016 end-page: 218 article-title: Implementing the use of a brief cognitive assessment on individuals diagnosed with schizophrenia in an acute psychiatric facility publication-title: Arch. Psychiatr. Nurs. – volume: 1 start-page: 272 year: 2017 end-page: 277 article-title: Effectiveness of electroconvulsive therapy and associated cognitive change in schizophrenia publication-title: J. ECT – volume: 15 start-page: 346 year: 2009 end-page: 368 article-title: Electroconvulsive therapy: Part I. A perspective on the evolution and current practice of ECT publication-title: J. Psychiatr. Pract. – volume: 246 start-page: 246 year: 2016 end-page: 249 article-title: Electroconvulsive therapy and its relationships with clinical characteristics and quality of life in Chinese psychiatric patients publication-title: Psychiatry Res. – volume: 6 start-page: 210 year: 2013 end-page: 217 article-title: Double‐blind randomized controlled study showing symptomatic and cognitive superiority of bifrontal over bitemporal electrode placement during electroconvulsive therapy for schizophrenia publication-title: Brain Stimul. – volume: 10 start-page: 178 year: 1998 end-page: 186 article-title: Changes in seizure threshold over the course of electroconvulsive therapy affect therapeutic response and are detected by ictal EEG ratings publication-title: J. Neuropsychiatry Clin. Neurosci. – volume: 3 start-page: 77 year: 2006 end-page: 87 article-title: Sensitivity to change of the Brief Psychiatric Rating Scale‐Extended (BPRS‐E): An item and subscale analysis publication-title: Psychol. Serv. – volume: 15 start-page: 202 year: 1999 end-page: 206 article-title: Speed of response to bilateral ECT: An examination of possible predictors in two controlled trials publication-title: J. ECT – volume: 162 start-page: 441 year: 2005 end-page: 449 article-title: Remission in schizophrenia: Proposed criteria and rationale for consensus publication-title: Am. J. Psychiatry – volume: 68 start-page: 568 year: 2010 end-page: 577 article-title: Objective cognitive performance associated with electroconvulsive therapy for depression: A systematic review and meta‐analysis publication-title: Biol. Psychiatry – volume: 126 start-page: 330 year: 2010 end-page: 333 article-title: Low dose lignocaine added to propofol does not attenuate the response to electroconvulsive therapy publication-title: J. Affect. Disord. – volume: 29 start-page: 321 year: 1993 end-page: 326 article-title: Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure publication-title: Psychopharmacol. Bull. – volume: 158 start-page: 151 year: 2014 end-page: 155 article-title: A pilot study to measure cognitive impairment in patients with severe schizophrenia with the Montreal Cognitive Assessment (MoCA) publication-title: Schizophr. Res. – volume: 62 start-page: 772 year: 2017 end-page: 777 article-title: Clozapine response rates among people with treatment‐resistant schizophrenia: Data from a systematic review and meta‐analysis publication-title: Can. J. Psychiatry – volume: 11 start-page: 167 year: 1984 end-page: 176 article-title: The efficiency of ECT: I. Response rate in depressive episodes publication-title: Psychiatry Res. – volume: 33 start-page: 1225 year: 2007 end-page: 1237 article-title: Psychiatric symptoms and quality of life in schizophrenia: A meta‐analysis publication-title: Schizophr. Bull. – volume: 285 start-page: S279 year: 2009 article-title: PO23‐TH‐05 Montreal Cognitive Assessment (MoCA): Correlation with existing cognitive tests for mild cognitive impairment in Singapore publication-title: J. Neurol. Sci. – volume: 63 start-page: 189 year: 2003 end-page: 193 article-title: Acute and maintenance ECT with flupenthixol in refractory schizophrenia: Sustained improvements in psychopathology, quality of life, and social outcomes publication-title: Schizophr. Res. – volume: 11 start-page: 177 year: 2015 end-page: 183 article-title: Correlation between changes in quality of life and symptomatic improvement in Chinese patients switched from typical antipsychotics to olanzapine publication-title: Neuropsychiatr. Dis. Treat. – year: 2012 – volume: 174 start-page: 113 year: 2016 end-page: 119 article-title: Reasons for discontinuing clozapine: A cohort study of patients commencing treatment publication-title: Schizophr. Res. – volume: 172 start-page: 52 year: 2015 end-page: 58 article-title: Electroconvulsive therapy augmentation in clozapine‐resistant schizophrenia: A prospective, randomized study publication-title: Am. J. Psychiatry – volume: 20 start-page: 154 year: 2004 end-page: 159 article-title: A study into predictors for the speed of response to electroconvulsive therapy publication-title: J. ECT – volume: 196 start-page: 226 year: 2010 end-page: 234 article-title: Bifrontal, bitemporal and right unilateral electrode placement in ECT: Randomised trial publication-title: Br. J. Psychiatry – volume: 27 start-page: 206 year: 2015 end-page: 219 article-title: Efficacy and safety of treating patients with refractory schizophrenia with antipsychotic medication and adjunctive electroconvulsive therapy: A systematic review and meta‐analysis publication-title: Shanghai Arch. Psychiatry – volume: 78 start-page: e383 year: 2017 end-page: e389 article-title: Clinical effectiveness and cognitive impact of electroconvulsive therapy for schizophrenia publication-title: J. Clin. Psychiatry – volume: 28 start-page: 185 year: 2013 end-page: 189 article-title: In patients with schizophrenia, symptoms improvement can be uncorrelated with quality of life improvement publication-title: Eur. Psychiatry – volume: 133 start-page: 17 year: 2011 end-page: 21 article-title: Association between symptoms and quality of life in patients with schizophrenia: A pooled analysis of changes over time publication-title: Schizophr. Res. – volume: 42 start-page: 496 year: 2008 end-page: 504 article-title: Relationships between cognitive deficits, symptoms and quality of life in schizophrenia publication-title: Aust. N. Z. J. Psychiatry – volume: 174 start-page: 216 year: 2017 end-page: 229 article-title: Treatment‐resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology publication-title: Am. J. Psychiatry – volume: 10 start-page: 799 year: 1962 end-page: 812 article-title: The Brief Psychiatric Rating Scale publication-title: Psychol. Rep. – volume: 20 start-page: 1727 year: 2011 end-page: 1736 article-title: Development and preliminary testing of the new five‐level version of EQ‐5D (EQ‐5D‐5L) publication-title: Qual. Life Res. – volume: 133 start-page: 641 year: 2011 end-page: 644 article-title: Quality of life after electroconvulsive therapy in persons with treatment resistant schizophrenia publication-title: Indian J. Med. Res. – volume: 261 start-page: 425 year: 2011 end-page: 432 article-title: Electroconvulsive therapy for treating schizophrenia: A chart review of patients from two catchment areas publication-title: Eur. Arch. Psychiatry Clin. Neurosci. – volume: 26 start-page: 289 year: 2010 end-page: 298 article-title: Electroconvulsive therapy in treatment‐resistant schizophrenia publication-title: J. ECT – volume: 12 start-page: 147 year: 1996 end-page: 151 article-title: Relationship of seizure morphology to the convulsive threshold publication-title: Convuls. Ther. – volume: 11 start-page: 2041 year: 2015 end-page: 2048 article-title: Relationship between cognitive insight and subjective quality of life in outpatients with schizophrenia publication-title: Neuropsychiatr. Dis. Treat. – volume: 98 start-page: 201 year: 2008 end-page: 208 article-title: Subjective and objective quality of life in schizophrenia publication-title: Schizophr. Res. – volume: 360 start-page: 1437 year: 2009 end-page: 1444 article-title: Medical evaluation of patients undergoing electroconvulsive therapy publication-title: N. Engl. J. Med. – ident: e_1_2_7_37_1 doi: 10.1016/j.eurpsy.2011.10.002 – ident: e_1_2_7_17_1 doi: 10.1097/YCT.0000000000000422 – ident: e_1_2_7_5_1 doi: 10.4088/JCP.16m10686 – ident: e_1_2_7_8_1 doi: 10.1007/s00406-010-0173-3 – ident: e_1_2_7_18_1 doi: 10.1016/j.brs.2012.04.002 – ident: e_1_2_7_14_1 – volume: 27 start-page: 206 year: 2015 ident: e_1_2_7_30_1 article-title: Efficacy and safety of treating patients with refractory schizophrenia with antipsychotic medication and adjunctive electroconvulsive therapy: A systematic review and meta‐analysis publication-title: Shanghai Arch. Psychiatry – ident: e_1_2_7_10_1 doi: 10.1097/00124509-200409000-00006 – ident: e_1_2_7_19_1 doi: 10.1192/bjp.bp.109.066183 – ident: e_1_2_7_41_1 doi: 10.1016/j.schres.2007.09.001 – ident: e_1_2_7_33_1 doi: 10.1016/j.apnu.2015.08.016 – ident: e_1_2_7_38_1 doi: 10.1093/schbul/sbl071 – ident: e_1_2_7_12_1 doi: 10.1016/0165-1781(84)90065-9 – ident: e_1_2_7_15_1 doi: 10.1176/appi.ajp.2016.16050503 – ident: e_1_2_7_31_1 doi: 10.1016/j.biopsych.2010.06.009 – volume: 133 start-page: 641 year: 2011 ident: e_1_2_7_34_1 article-title: Quality of life after electroconvulsive therapy in persons with treatment resistant schizophrenia publication-title: Indian J. Med. Res. – ident: e_1_2_7_2_1 doi: 10.1177/0706743717718167 – ident: e_1_2_7_26_1 doi: 10.1007/s11136-011-9903-x – ident: e_1_2_7_6_1 doi: 10.1016/S0920-9964(02)00330-4 – ident: e_1_2_7_20_1 doi: 10.1016/j.jad.2010.02.134 – ident: e_1_2_7_7_1 doi: 10.1097/YCT.0b013e3181cb5e0f – ident: e_1_2_7_29_1 doi: 10.1037/1541-1559.3.2.77 – ident: e_1_2_7_42_1 doi: 10.2147/NDT.S90143 – ident: e_1_2_7_28_1 doi: 10.1176/appi.ajp.162.3.441 – ident: e_1_2_7_36_1 doi: 10.1016/j.schres.2011.09.021 – ident: e_1_2_7_27_1 doi: 10.1016/S0022-510X(09)71062-7 – ident: e_1_2_7_13_1 doi: 10.1097/01.pra.0000361277.65468.ef – volume: 16 start-page: 127 year: 2014 ident: e_1_2_7_9_1 article-title: A history of health‐related quality of life outcomes in psychiatry publication-title: Dialogues Clin. Neurosci. doi: 10.31887/DCNS.2014.16.2/drevicki – volume: 12 start-page: 147 year: 1996 ident: e_1_2_7_23_1 article-title: Relationship of seizure morphology to the convulsive threshold publication-title: Convuls. Ther. – ident: e_1_2_7_16_1 doi: 10.1056/NEJMra0707755 – ident: e_1_2_7_24_1 doi: 10.2466/pr0.1962.10.3.799 – ident: e_1_2_7_32_1 doi: 10.1016/j.schres.2014.07.006 – ident: e_1_2_7_3_1 doi: 10.1016/j.schres.2016.05.002 – ident: e_1_2_7_35_1 doi: 10.1016/j.psychres.2016.09.046 – ident: e_1_2_7_11_1 doi: 10.1097/00124509-199909000-00004 – ident: e_1_2_7_40_1 doi: 10.1080/00048670802050512 – ident: e_1_2_7_21_1 doi: 10.1176/jnp.10.2.178 – ident: e_1_2_7_39_1 doi: 10.2147/NDT.S73992 – ident: e_1_2_7_22_1 doi: 10.1097/01.yct.0000235922.14623.39 – volume: 29 start-page: 321 year: 1993 ident: e_1_2_7_25_1 article-title: Quality of Life Enjoyment and Satisfaction Questionnaire: A new measure publication-title: Psychopharmacol. Bull. – ident: e_1_2_7_4_1 doi: 10.1176/appi.ajp.2014.13060787
SSID	ssj0003361
Score	2.4115703
Snippet	Aim Although electroconvulsive therapy (ECT) has been shown to be efficacious for patients with treatment‐resistant schizophrenia, there has been limited... Although electroconvulsive therapy (ECT) has been shown to be efficacious for patients with treatment-resistant schizophrenia, there has been limited evidence... AimAlthough electroconvulsive therapy (ECT) has been shown to be efficacious for patients with treatment‐resistant schizophrenia, there has been limited...
SourceID	proquest pubmed crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	416
SubjectTerms	Adult cognition Cognitive ability Electroconvulsive Therapy Female Humans Male Mental disorders Middle Aged neurostimulation Patients Psychiatric Status Rating Scales Psychosis Quality of Life Retrospective Studies Schizophrenia Schizophrenia - therapy Time Factors Treatment Outcome Treatment resistance treatment‐resistant schizophrenia Young Adult
Title	Clinical effectiveness and speed of response of electroconvulsive therapy in treatment‐resistant schizophrenia
URI	https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fpcn.12855 https://www.ncbi.nlm.nih.gov/pubmed/31026106 https://www.proquest.com/docview/2254826988 https://www.proquest.com/docview/2216293212
Volume	73
WOSCitedRecordID	wos000474931200008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library customDbUrl: eissn: 1440-1819 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003361 issn: 1323-1316 databaseCode: WIN dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1440-1819 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003361 issn: 1323-1316 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1PS-QwFH_ojMhednXXP-O6Q1w8eOmSNGma4EncHRR0EFGcW2naFIShM0xnFrz5EfyM-0l8aTNFcYWFvZS0fSUh79_vNS8vAIecGmWsLgKRZyleKA-MFiYoXK01dCehKOqS-RfxcKhGI321AsfLvTBNfYj2h5vTjNpeOwVPTfVCyadZ-QONaxStQjdEuY060P15Pbi9aA0x59LHWzxgnElfWMgl8rQfv3ZHbzDma8ha-5zBp_8a7QZ89FCTnDSysQkrtvwM65d-Mf0LTH1N0DFpkjq83SNpmZNqil6NTAoya3JorWv7I3Ncovpi7NLeSbN764Hcl6TNWP_z-IQfOVhazkn1MqdvC24Hv25OzwJ_AEOQiVhFgdUqzvPQCM1CJmkmLZe8YNIynVtNTYbPo1BZnaYsC9FsipQVERWxEZaalPJt6JST0u4C4ciP3MTUmJAhBsyVZlpwWXAqCkTOeQ-OlnxIMl-d3B2SMU6WUQrOYFLPYA--t6TTpiTH34j2l8xMvFZWCdougeGUVqoHB-1r1Ce3SJKWdrJwNEwiBEKP3oOdRgjaXhAKY8BJJQ625vX73SdXp8O6sffvpF_hA6Ix3eQC70NnPlvYb7CW_Z7fV7M-rMYj1fcijnd358NnbucALQ
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED-ydmx76bZ2H-nHppY-9MVFsmTZgr6UsJKwxOQhZXkzli1DITgmH4O97U_Y37i_ZCdbMQlrYbAXI-wTFjrd3e-k0x3AJac60kYVnsizFB-Ue1oJ7RU21xqaE18Udcr8YRjH0XSqxh242dyFafJDtBtuVjJqfW0F3G5Ib0l5lZXXqF2D4BnsCwQatnDDt0Hc6mHOpXO3uMc4ky6vkI3jabvuWqO_IOYuYq1Nzt3r_xvsGzhwUJPcNmvjLXRMeQgvRu4w_QgqlxN0RpqgDqf3SFrmZFmhVSPzgiyaGFpj265kjg1UX89s2Dtpbm_9IA8laSPWf__8hZ0sLC1XZLkd0_cO7u--THp9zxVg8DIRRoFnVBTmua-FYj6TNJOGS14waZjKjaI6w_eBHxmVpizzUW2KlBUBFaEWhuqU8vewV85L8xEIR4bkOqRa-wwxYB4ppgSXBaeiQOScd-Fqw4gkc9nJbZGMWbLxUnAGk3oGu3DRklZNSo7HiE433EycVC4T1F0C3SkVRV04bz-jPNlDkrQ087WlYRIhEFr0LnxoVkH7F4TC6HBSiYOtmf3075NxL64bx_9O-hle9iejYTIcxF9P4BUiM9XEBZ_C3mqxNmfwPPu-elguPtXr_A-ZzwD4
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NatwwEB6STQi99CdJ222SRik95OIgWbJsQS4lydKS7bKEBHIzliVBYPGa_Qnk1kfoM_ZJOrK1JqEpFHoxwh4hodHMfGONZgA-c6ozbZWLhCkLfFAeaSV05HyuNTQnsXBNyvxhOhplt7dqvAanq7swbX6I7oebl4xGX3sBt7Vxj6S8LqsT1K5Jsg4bwheR6cHG-dXgZthpYs5lcLh4xDiTIbOQj-TpOj-1R3-AzKeYtTE6g1f_N93X8DKATfKl3R1vYM1W27D1PRyn70AdsoJOSBvWETQfKSpD5jXaNTJ1ZNZG0VrfDkVzfKj6cuID30l7f-uB3FWki1n_9eMndvLAtFqQ-eOovl24GVxcn32NQgmGqBRplkRWZakxsRaKxUzSUlouuWPSMmWsorrE90mcWVUUrIxRcYqCuYSKVAtLdUH5W-hV08q-B8KRIUanVOuYIQo0mWJKcOk4FQ6xs-nD8YoReRnyk_syGZN85afgCubNCvbhU0dat0k5niPaX3EzD3I5z1F7CXSoVJb14aj7jBLlj0mKyk6XnoZJBEFo0_vwrt0F3SgIhtHlpBIn2zD778Pn47NR0_jw76SHsDU-H-TDb6PLPXiB0Ey1gcH70FvMlvYANsv7xd189jFs9N81cQGh
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+effectiveness+and+speed+of+response+of+electroconvulsive+therapy+in+treatment%E2%80%90resistant+schizophrenia&rft.jtitle=Psychiatry+and+clinical+neurosciences&rft.au=Chan%2C+Christopher+Yi+Wen&rft.au=Abdin%2C+Edimansyah&rft.au=Seow%2C+Esmond&rft.au=Subramaniam%2C+Mythily&rft.date=2019-07-01&rft.pub=John+Wiley+%26+Sons+Australia%2C+Ltd&rft.issn=1323-1316&rft.eissn=1440-1819&rft.volume=73&rft.issue=7&rft.spage=416&rft.epage=422&rft_id=info:doi/10.1111%2Fpcn.12855&rft.externalDBID=10.1111%252Fpcn.12855&rft.externalDocID=PCN12855
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1323-1316&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1323-1316&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1323-1316&client=summon